Study of QN-302 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called QN-302 in people with advanced solid tumors that have grown despite standard treatments or for which no standard therapy exists. The goal is to see if it is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed solid tumor that has spread or cannot be removed by surgery.
- Your tumor must have continued to grow after you tried all available standard treatments, or no standard treatment exists for your cancer type.
- Your cancer must be measurable or evaluable using standard scans or tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This trial tests a new combination of drugs for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and improve outcomes.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests an experimental drug (called QLS5308) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug can shrink tumors or slow their growth, and to find the best dose with manageable side effects.
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.